SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is trending downwards as the broader crypto market experiences a pullback, sparking discussions about potential support levels and whether this is a temporary dip or a longer-term correction. The community is debating the influence of large holders and potential market manipulation, while also considering historical patterns and future catalysts. Some traders are expressing concern and urging caution, while others see this as a buying opportunity.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending downwards as the community debates whether recent drops are a market correction or the start of a longer-term decline, with some citing strong earnings and jobs data as reasons for potential bounces. Concerns around AI's impact and comparisons to past market downturns are fueling bearish sentiment, while others anticipate a rally into the holiday season. Traders are closely watching key support levels and VIX for potential market direction cues.

Bitmine Immersion Technologies, Inc. is a blockchain technology company, which engages in industrial scale digital asset mining, equipment sales, and hosting operations. It operates through the Cryptocurrency Mining Industry segment. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

Bitmine Immersion Technologies is trending downwards as the community expresses concerns over its large Ethereum holdings amidst a broader crypto downturn, with many pointing to unrealized losses and the potential impact of upcoming earnings. Discussions revolve around the company's strategy, particularly regarding staking, and whether CEO Tom Lee can address investor anxieties. Some traders speculate on coordinated short attacks, while others see a buying opportunity if the company starts staking.

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPY is trending amid a sharp market reversal driven by concerns about future rate cuts and disappointing reactions to tech earnings, sparking community discussion on potential support levels and market manipulation. Community members are debating whether this is a temporary pullback or the start of a larger correction, with some pointing to potential negative catalysts while others anticipate a bounce. Discussions also involve the impact of political factors and the unwinding of carry trades on market sentiment.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull Corp ($BULL) is trending amidst community discussion surrounding its earnings report and potential growth prospects, with some investors comparing it to Robinhood ($HOOD). Despite positive earnings, some express concerns about the overall market conditions impacting the stock, while others anticipate a potential short squeeze and future gains.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Strategy (MSTR) is trending downwards as Bitcoin's recent volatility sparks concerns about the company's heavy investment in the cryptocurrency and potential margin calls. The community is actively discussing downside risk, potential bankruptcy scenarios, and the impact of prominent figures like Jim Cramer and Michael Saylor on the stock's future, questioning its correlation with Bitcoin's price movements.

Walmart, Inc. engages in the retail and wholesale business. The company offers an assortment of merchandise and services at everyday low prices. It operates through the following business segments: Walmart U.S., Walmart International, and Sam's Club. The Walmart U.S. segment operates as a mass merchandiser of consumer products, operating under the Walmart and Walmart Neighborhood Market brands, including walmart.com. The Walmart International segment includes operations of wholly-owned subsidiaries in Canada, Chile, China, and Africa, and majority-owned subsidiaries in India, as well as Mexico and Central America. The Sam's Club segment manages membership-only warehouse clubs and operates samsclub.com. The company was founded by Samuel Moore Walton and James Lawrence Walton on July 2, 1962 and is headquartered in Bentonville, AR.

Walmart Inc

Walmart is trending as investors assess its stability amid broader market uncertainty and an upcoming earnings report, with some highlighting its potential to capture market share from competitors. The community is also discussing Walmart's AI initiatives and the impact of consumer spending trends on its performance. Additionally, Walmart's recent announcement of a CEO transition is being monitored for its potential impact on the company's strategic direction.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron is trending amid a volatile trading session, driven by reactions to increased capital expenditure plans and anticipation for Nvidia's upcoming earnings report. Community members are actively debating whether the recent pullback presents a buying opportunity or signals an overbought condition, with some citing strong fundamentals and rising memory prices, while others point to potential overvaluation and cyclical concerns within the semiconductor sector.

BlackRock Institutional Trust Company N.A. - iShares Russell 2000 ETF

iShares Russell 2000 ETF

IWM is trending as traders assess its recent pullback and potential for a rebound, with some noting its relative strength compared to tech. Community members are actively discussing key support and resistance levels, put/call flows, and the potential impact of upcoming economic data and $NVDA earnings on small caps. Overall sentiment appears mixed, with both bullish and bearish viewpoints being shared.

Intuit, Inc. engages in the provision of business and financial management solutions. It operates through the following segments: Small Business and Self-Employed, Consumer, Credit Karma, and ProTax. The Small Business and Self-Employed segment offers QuickBooks financial and business management online services and desktop software, payroll solutions, payment processing solutions, and financing for small businesses. The Consumer segment includes do-it-yourself and assisted TurboTax income tax preparation products and services. The Credit Karma segment serves consumers with a personal finance platform that provides personalized recommendations of credit cards, home, auto and personal loans, and insurance products, and online savings and checking accounts. The ProTax segment refers to the professional accountants in the U.S. and Canada, who are essential to both small business success and tax preparation and filing. The company was founded by Scott D. Cook and Thomas A. Proulx in March 1983 and is headquartered in Mountain View, CA.

Intuit Inc

Intuit ($INTU) is trending due to recent earnings reports and subsequent analyst activity, with some community members pointing to strong financial results, particularly driven by AI integration and TurboTax Live. However, there are concerns about the company's valuation and potential impact from tariffs on small businesses, creating mixed sentiment, especially regarding the AI impact on productivity for end users. The stock's price movement and future growth potential are key discussion points among investors.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>In Q3, the company’s revenue increased 20% to $13.5 billion.&nbsp;</li><li>While revenue from the company’s delivery segment rose 29% to $4.5 billion in the quarter, revenue from the mobility segment grew 20% to $7.7 billion, even as freight division revenue remained flat year-on-year.</li><li>Adjusted EBITDA rose 33% to $2.3 billion in the quarter, above an analyst estimate of $2.27 billion. &nbsp;</li></ul>Uber Technologies, Inc. (UBER) reported a stronger-than-expected third-quarter earnings, but a soft forecast for the forthcoming quarter weighed on investor sentiment, sending its shares lower in the pre-market session.The ride-hailing firm now <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investor.uber.com/news-events/news/press-release-details/2025/Uber-Announces-Results-for-Third-Quarter-2025/default.aspx">expects</a> gross bookings in the fourth quarter to be between $52.25 billion and $53.75 billion, representing a year-over-year growth of 17% to 21% on a constant currency basis.Adjusted Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) in the busiest quarter of the year is expected to be $2.41 billion to $2.51 billion, representing 31% to 36% growth. This is, however, marginally below the $2.49 billion expected by Wall Street analysts.<h2 class="st-heading-2">Q3 Numbers</h2>In the third quarter, the company’s revenue increased 20% to $13.5 billion, driven by a 21% rise in gross bookings to $49.7 billion, primarily due to growth in the company’s mobility and delivery businesses. This is higher than the $13.3 billion expected by analysts, according to data from Fiscal AI.Trips in the quarter grew 22% to 3.5 billion, marking the largest trip volume increase in Uber’s history outside the post-COVID-19 rebound, CEO Dara Khosrowshahi noted.While revenue from the company’s delivery segment rose 29% to $4.5 billion in the quarter, revenue from the mobility segment grew 20% to $7.7 billion, even as freight division revenue remained flat year-on-year. The company is now expanding its delivery business with partnerships with more grocery and retail merchants.Uber's adjusted EBITDA rose 33% to $2.3 billion in the quarter, above an analyst estimate of $2.27 billion.<h2 class="st-heading-2">How Did Stocktwits User React?</h2><a href="https://stocktwits.com/symbol/UBER">Uber shares </a>slipped 7% in the pre-market session at the time of writing. On Stocktwits, retail sentiment around Uber stayed within the 'bullish' territory over the past 24 hours, while message volume rose from 'high' to 'extremely high' levels.UBER stock is up by 65% this year and by about 36% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-china-made-ev-sales-reportedly-drop-10-percent-in-october/cL28BCjR3CD">Tesla’s China-Made EV Sales Reportedly Drop 10% In October, Lowest Since May</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Uber Technologies Inc logo is seen displayed on a smartphone screen. 

Uber Delivers Solid Earnings, But Tepid Q4 Guidance Sends Stock Lower 

The company now expects adjusted EBITDA in Q4 to be $2.41 billion to $2.51 billion, marginally below an analyst estimate of $2.49 billion. 

Equity

The company now expects adjusted EBITDA in Q4 to be $2.41 billion to $2.51 billion, marginally below an analyst estimate of $2.49 billion. 


<ul class="summary-bullets"><li>The pharma major now expects adjusted earnings in the range of $3.00 to $3.15 for the full year.&nbsp;</li><li>Q3 revenue totaled $16.7 billion, down 6% year-over-year due to a decline in COVID-19 product revenues.</li><li>Revenues from the company’s anticoagulant Eliquis, however, rose 25% to $2.02 billion, driven by higher demand.&nbsp; &nbsp;</li></ul>Pfizer Inc. (PFE) on Tuesday raised its full-year adjusted earnings guidance to a range of $3.00 to $3.15, citing continued confidence in the business and progress with ongoing cost improvement initiatives.The company was previously expecting adjusted earnings in the range of $2.90 to $3.10 per share. Pfizer is now on track to deliver approximately $7.2 billion in overall anticipated net cost savings by the end of 2027, driven by cost improvement initiatives announced previously.The pharma major also <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://s206.q4cdn.com/795948973/files/doc_financials/2025/q3/Q3-2025-PFE-Earnings-Release-FINAL.pdf">reaffirmed</a> its full-year revenue guidance of $61.0 billion to $64.0 billion.<h2 class="st-heading-2">Q3 Earnings &nbsp;</h2>For the third quarter, the company reported adjusted earnings per share of $0.87, down from the $1.06 reported in the corresponding period of 2024, but above an analyst estimate of $0.64, according to data from Fiscal AI.Revenue for the three months through the end of September totaled $16.7 billion, down 6% year-over-year due to a decline in COVID-19 product revenues, but above the estimated $16.5 billion.The company’s Paxlovid, an antiviral medication used to treat COVID-19, and its anti-COVID-19 vaccine Comirnaty, saw revenues in the quarter down by 55% and 19%, respectively, on a total basis.Revenues from the company’s anticoagulant Eliquis, however, rose 25% to $2.02 billion, driven by higher demand. Other drugs to see revenue growth in the quarter include the heart disease drug Vyndaqel, which experienced a 10% increase to $ 1.59 billion.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Shares of the company traded 1% lower in the pre-market session at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/PFE">PFE stock</a> jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.PFE stock is down 7% this year and approximately 11% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-china-made-ev-sales-reportedly-drop-10-percent-in-october/cL28BCjR3CD">Tesla’s China-Made EV Sales Reportedly Drop 10% In October, Lowest Since May</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Optimism has also been recently driven by Pfizer’s solid quarterly performance.

Pfizer Raises Full-Year Earnings Guidance, Q3 Numbers Beat Street Estimates

The company noted that it is on track to deliver about $7.2 billion in overall anticipated net cost savings by the end of 2027. 

<ul><li>American Airlines said that Pieper joins the company after serving as oneworld CEO since April 2024.</li><li>Before joining oneworld, Pieper spent more than 25 years in commercial and finance leadership positions at Alaska Air Group, Delta Air Lines and Northwest Airlines.</li><li>According to a CNBC report, the appointment of Pieper comes on the heels of American Airlines removing its former chief commercial officer, Vasu Raja, in 2024.</li></ul>American Airlines said on Thursday it has appointed Nathaniel Pieper as its new chief commercial officer, effective November 3, and that he will report to CEO Robert Isom.According to a <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.cnbc.com/2025/10/23/american-airlines-nat-pieper.html">CNBC report</a>, Pieper's appointment comes on the heels of American removing its former chief commercial officer, Vasu Raja, in 2024 after his approach to business travel misfired, leading to resistance from corporate travel agencies.<h2 class="st-heading-2">Pieper’s Experience In Aviation Industry</h2>Pieper is an aviation executive with nearly 30 years of industry experience. The company said Pieper joins American after serving as oneworld CEO since April 2024. During his tenure, he integrated two new airlines into oneworld and launched sustainability and customer experience initiatives.American Airlines said that before joining oneworld, Pieper spent more than 25 years in commercial and finance leadership positions at Alaska Air Group, Delta Air Lines, and Northwest Airlines. As Senior Vice President at Alaska Air Group, he spearheaded Alaska’s entrance into oneworld and constructed a commercial partnership with American Airlines linking domestic and international flying.<h2 class="st-heading-2">American Airlines Third-Quarter Results</h2>Earlier on Thursday, American Airlines reported third-quarter revenue of $13.69 billion, compared with Wall Street expectations of $13.63 billion, according to data compiled by Fiscal AI.Its adjusted loss per share came in at $0.17, compared with an estimated loss of $0.28. American Airlines now expects full-year adjusted earnings per share between $0.65 and $0.95, compared with its prior forecasted&nbsp;range between a loss of $0.20 and a profit of $0.80.The company said the premium segment’s unit revenue growth year over year continues to outpace that of the main cabin segment, echoing similar comments from United Airlines.Retail sentiment on American Airlines improved to ‘bullish’ from ‘neutral’ territory compared to a day ago, with message volumes at ‘high’ levels, according to data from Stocktwits.<a href="https://stocktwits.com/symbol/AAL">Shares of American Airlines</a> rose nearly 5% in afternoon trading.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/palantir-reportedly-lands-200-m-deal-with-lumen-alex-karp-says-it-will-be-about-accelerating-the-transformation-and-making-lots-of-money/cLG4hgoR3Av">Palantir Reportedly Lands $200M Deal With Lumen: Alex Karp Says It's All About Accelerating Transformation, And 'Making Lots Of Money'</a>

American Airlines planes are seen at Miami International Airport in Miami, United States on May 9, 2024. (Photo by Jakub Porzycki/NurPhoto via Getty Images)

American Airlines Names Aviation Veteran Nathaniel Pieper As Chief Commercial Officer

American Airlines said that Pieper joins the company after serving as oneworld CEO since April 2024.

Polaris (PII) stock witnessed price target hikes on Tuesday after the specialty vehicle manufacturer announced a deal to separate its Indian bike operations from its portfolio and into a standalone business.BofA analyst Alexander Perry raised the firm's price target on Polaris to $70 from $60 while keeping a ‘Neutral’ rating on the shares after the company agreed to sell a majority stake in Indian Motorcycle to California-headquartered private equity firm Carolwood, as per TheFly.Roth Capital analyst Scott Stember, meanwhile, raised the firm's price target on the stock to $54 from $41 and kept a ‘Neutral’ rating on the shares. While BofA’s new price target implies a potential upside of about 14% from the stock’s closing price on Monday, Roth Capital’s new target suggests a potential downside of about 12%.Shares of Polaris traded 13% higher on Tuesday at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/PII">PII stock</a> jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume increased from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:587/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_14_at_1_23_30_PM_png_136d55f245.webp" alt="PII's Sentiment Meter and Message Volume as of 1:23 p.m. ET on Oct. 14, 2025 | Source: Stocktwits" width="587" height="62"><figcaption>PII's Sentiment Meter and Message Volume as of 1:23 p.m. ET on Oct. 14, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user applauded the company’s move as a good decision.<stembedurl>https://stocktwits.com/Lying___Dandy/message/632206305</stembedurl>Polaris did not disclose the size of the deal with Carolwood on Monday but <a href="https://stocktwits.com/news-articles/markets/equity/polaris-stock-jumps-on-deal-to-sell-indian-bikes-brand/ch6mQ4ER3l1">said</a> the divestiture would boost Polaris's annualized adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) by about $50 million and annualized adjusted earnings by $1 a share. The closing of the transaction is expected in the first quarter of 2026.CEO Mike Speetzen said the sale would enable Polaris to focus on the parts of its business that have the most growth potential. However, the company said it would continue to maintain a small equity position in the Indian Motorcycle business after the closing of the transaction.Polaris also said on Monday that it expects third-quarter sales to be at the high end of its previously issued guidance range of $1.6 billion to $1.8 billion. The company now anticipates third-quarter adjusted earnings per share to be in the range of $0.31 to $0.41, higher than its original expectations.Speetzen said the higher expectations are driven by higher-than-expected shipments, strong cost management, and ongoing progress within operational efficiency initiatives.PII stock is up by 20% this year and down by about 15% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/novavax-major-shareholder-calls-for-sale-of-company-to-larger-pharma-entity/ch6moRsR3mh">Novavax Major Shareholder Calls For Sale Of Company To Larger Pharma Entity</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Bikes from Indian Motorcycle, owned by Polaris, at the Minneapolis Convention Center in 2014. (Photo By Marlin Levison/Star Tribune via Getty Images)

Polaris Stock Gets Price Target Hikes After Selling Indian Bike Business To Private Equity Firm

BofA analyst Alexander Perry raised the firm's price target on Polaris to $70 from $60 after the company agreed to sell a majority stake in Indian Motorcycle to California-headquartered private equity firm Carolwood.

Ford Motor Co. (F) CEO Jim Farley reportedly believes that the elimination of federal tax credit on the purchase of electric vehicles and other Trump policies will sharply curtail EV demand in the U.S.Farley predicted the share of zero-emission vehicles could decline by half, according to a Bloomberg <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-09-30/ford-s-ceo-sees-trump-policies-cutting-us-ev-market-in-half?srnd=homepage-americas">report</a>. ZEVs currently account for 10% of the domestic market.&nbsp;“I wouldn’t be surprised if EV sales in the U.S. go down to 5%,” Farley said at a conference in Detroit, as reported by Bloomberg. The CEO, however, said the company is looking to add hybrid production to its battery and EV plants, the report noted.<a href="https://stocktwits.com/symbol/F">Ford shares</a> traded 1% lower on Tuesday afternoon at the time of writing. On Stocktwits, retail sentiment around the stock stayed within the ‘bullish’ territory, while message volume stayed at ‘high’ levels.<figure class="image"><img style="aspect-ratio:625/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_30_at_2_06_42_PM_png_de870fd3da.webp" alt="F's Sentiment Meter and Message Volume as of 2:07 p.m. ET on Sept. 30, 2025 | Source: Stocktwits" width="625" height="63"><figcaption>F's Sentiment Meter and Message Volume as of 2:07 p.m. ET on Sept. 30, 2025 | Source: Stocktwits</figcaption></figure>In the second quarter, Ford’s EV segment, known as Model e, saw its operating loss widen to $1.3 billion, pressured by tariffs and ramp-up costs at its new battery plant in Marshall, Michigan.Ford’s current EV lineup in the U.S. is comprised of just three vehicles: the F-150 Lightning pickup truck, the Mustang Mach-E SUV, and the E-Transit van. This year, through the end of August, the company sold a cumulative 57,888 units of the three models, marking a drop of about 6% from the corresponding period last year, despite a 5.5% increase in internal combustion engine vehicles.Ford stated last month that it plans to introduce a new group of affordable electric vehicles starting in 2027 to expand its EV lineup. The first in line would be a midsize pickup truck assembled at Ford’s Louisville Assembly Plant with an expected starting price of $30,000, the company added.F stock is up by about 21% this year and by about 13% over the past 12 months.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/moonlake-immunotherapeutics-stock-draws-wall-street-attention-post-mondays-plunge/chDDKdWR39j">MoonLake Immunotherapeutics Stock Draws Wall Street Attention Post Monday’s Plunge: Retail Sees Significant Upside</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Ford Motor Company CEO Jim Farley speaks at a Ford Pro Accelerate event on September 30, 2025 in Detroit, Michigan. (Photo by Bill Pugliano/Getty Images)

Ford CEO Jim Farley Reportedly Expects US EV Demand To Decline Sharply – Here’s Why

According to a Bloomberg report, Farley predicted the share of zero-emission vehicles could fall by half. 

Bristol Myers Squibb (BMY) announced on Thursday that it will sell its moderate-to-severe plaque psoriasis drug, Sotyktu, at a discount of more than 80% to the current list price, starting in January 2026, to cash-paying patients.Patients can purchase the drug at a discount on the company’s BMS Patient Connect direct-to-patient platform. Eligible cash-paying U.S. patients with a Sotyktu prescription can buy the medicine through the platform, which offers shipping across all 50 states and Puerto Rico, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://news.bms.com/news/corporate-financial/2025/Bristol-Myers-Squibb-Builds-on-Eliquis-apixaban-Direct-to-Patient-Program-Announces-New-BMS-Patient-Connect-Platform-Offering-Sotyktu-deucravacitinib/default.aspx">stated</a>. The platform will also provide patient support resources, it added.“We are taking a leading role in removing barriers, providing transparency and lowering out-of-pocket costs so patients in the United States can get the treatments they need – delivered directly to their door, wherever they are in the country,” CEO Christopher Boerner said.The announcement comes on the heels of President Trump <a href="https://stocktwits.com/news-articles/markets/equity/trump-to-issue-60-day-warning-letters-to-drugmakers-over-pricing/choL0IMRdGB">sending</a> letters to 17 drugmakers demanding that they lower drug prices in the U.S. to levels paid by other wealthy nations. The deadline for meeting the demand is on Monday, and the White House has warned of action against those who do not comply.Shares of the company traded 0.3% higher in the pre-market session at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/BMY">BMY stock</a> rose from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.In July, the company also <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://google.com/url?q=https://stocktwits.com/news-articles/markets/equity/bristol-myers-pfizer-to-offer-blood-thinning-drug-at-discount/ch8K8XqR5pI&amp;sa=D&amp;source=docs&amp;ust=1758807238695403&amp;usg=AOvVaw1vujNK93MaBpbwKU9R5Fiv">announced</a> that it will sell its blood thinner drug Eliquis to cash-paying patients for more than 40% discount to the current list price. Eliquis is a prescription medicine used in adults to reduce the risk of stroke and blood clots in people who have atrial fibrillation (AFib), a type of irregular heartbeat, not caused by a heart valve problem. It is also used to treat blood clots in the veins of the legs or lungs, and reduce the risk of them occurring again after receiving treatment for blood clots.BMY stock is down approximately 22% this year and by about 12% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/capricor-stock-rises-pre-market-over-fresh-hopes-of-deramiocel-approval-in-treating-genetic-disorder/chDlIyZR34h">Capricor Stock Rises Pre-Market Over Fresh Hopes of Deramiocel Approval In Treating Genetic Disorder</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Bristol-Myers Squibb Company logo is seen displayed on a tablet. (Photo Illustration by Igor Golovniov/SOPA Images/LightRocket via Getty Images)

Bristol Myers To Sell Plaque Psoriasis Drug For Over 80% Discount Starting In 2026

Patients can purchase the drug at a discount on the company’s BMS Patient Connect direct-to-patient platform.

Harmony Biosciences Holdings (HRMY) on Wednesday said that its late-stage study of ZYN002 in Fragile X syndrome did not meet the primary endpoint of improvement in social avoidance.Fragile X syndrome (FXS) is a rare genetic disorder that negatively affects synaptic function, plasticity, and neuronal connections. It results in a spectrum of intellectual disabilities and behavioral symptoms, such as social avoidance and irritability. According to the company, the disease affects upwards of 80,000 patients in the U.S. and 121,000 patients in the European Union and the U.K. The disease is more common in males than females, but there are no FDA-approved treatments for the disorder.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.harmonybiosciences.com/news-releases/news-release-details/harmony-biosciences-provides-update-its-phase-3-reconnect-study">said</a> on Wednesday that its drug did not meet the primary endpoint of the trial primarily due to a higher-than-expected placebo response rate.Shares of HRMY traded 15% lower at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/HRMY">HRMY stock</a> rose from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:575/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_24_at_1_01_23_PM_png_17fb739829.webp" alt="HRMY's Sentiment Meter and Message Volume as of 1:01 p.m. ET on Sept. 24, 2025 | Source: Stocktwits" width="575" height="62"><figcaption>HRMY's Sentiment Meter and Message Volume as of 1:01 p.m. ET on Sept. 24, 2025 | Source: Stocktwits</figcaption></figure>Chief Medical Officer Kumar Budur stated that, although the study's findings did not meet the primary endpoint, they provide valuable insights into Fragile X syndrome. “We will conduct a comprehensive analysis of the full dataset to better understand the results as part of our continued commitment to the Fragile X community,” Budur said.The trial, which enrolled 215 patients with FXS aged 3 to under 30 years, aimed to assess the efficacy and safety of ZYN002, a pharmaceutically manufactured synthetic cannabidiol.CEO Jeffrey M. Dayno stated that the company has additional candidates in its pipeline. “We have a late-stage, catalyst-rich pipeline with multiple Phase 3 programs in the clinic and continue to be on track to initiate our Phase 3 trials for pitolisant HD in narcolepsy and idiopathic hypersomnia in the fourth quarter of this year,” he said.HRMY stock is down by 21% this year and by 28% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/honda-motor-reportedly-ends-us-production-of-acura-zdx-ev/chD14gFR33x">Honda Motor Reportedly Ends US Production Of Acura ZDX EV</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Harmony Biosciences Stock Slumps After Rare Genetic Disorder Drug Fails Late-Stage Study

The company said on Wednesday that its drug did not meet the primary endpoint of the trial primarily due to a higher-than-expected placebo response rate.

Activist hedge fund Engine Capital is reportedly pushing Acadia Healthcare (ACHC) to refresh its board as it faces multiple federal investigations.According to a <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.ft.com/content/e96d221b-c275-4b3e-86aa-250f784d55dc">report</a> by The Financial Times, the fund holds a roughly 3% stake in Acadia and has written a letter to the company's board, requesting a review of its asset portfolio, improvements to its board of directors, and the halting of capital-intensive projects for new facilities.Acadia provides for-profit behavioral healthcare services. It is currently facing probes from the Department of Justice and Securities and Exchange Commission over allegations of holding patients against their will and falsifying insurance claims, the report noted.Shares of the company rose over 8% on Wednesday morning following the news. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ACHC">ACHC</a> stayed within the ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘normal’ levels.Tennessee-headquartered Acadia operated a network of 274 behavioral healthcare facilities, including inpatient psychiatric hospitals, specialty treatment facilities, residential treatment centers, and outpatient clinics, with approximately 12,100 beds in 39 states and Puerto Rico as of the end of June. The company estimates that it serves more than 82,000 patients daily.As per FT, Engine Capital accused Acadia of maintaining a “growth at any cost” approach in its letter. It alleged that the approach has given rise to a bloated corporate structure and noted that a 2022 reorganisation left the company with an unwieldy management structure that has stifled the company’s turnaround.The firm also urged the company to add new directors with experience in behavioral health and capital allocation, while noting that the current board has no director with relevant operating experience. The hedge fund also encouraged the company to consider selling its assets and repurchasing shares.ACHC stock is down 40% this year and approximately 69% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/uniqure-stock-rises-pre-market-after-investigational-huntingtons-disease-drug-slows-disease-in-trial/chD1GAOR33X">uniQure Stock Rises Pre-Market After Investigational Huntington’s Disease Drug Slows Disease In Trial</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration an Acadia Healthcare logo is seen on a smartphone and a pc screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

Acadia Healthcare Stock Surges After Activist Hedge Fund Reportedly Seeks Board Revamp

According to a report by The Financial Times, the fund has written a letter to the company's board, requesting a review of its asset portfolio and improvements to its board.

According to a report by The Financial Times, the fund holds a roughly 3% stake in Acadia and has written a letter to the company's board, requesting a review of its asset portfolio, improvements to its board, and the halting of capital-intensive projects for new facilities.

Acadia Pharmaceuticals Inc. (ACAD) announced on Tuesday that its late-stage intranasal Carbetocin trial in Prader-Willi syndrome (PWS) patients did not achieve a statistically significant improvement in hyperphagia.The <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://acadia.com/en-us/media/news-releases/acadia-pharmaceuticals-announces-phase-3-compass-pws-trial">study</a> enrolled 175 children and adults aged five to 30 years with PWS, a rare genetic disorder characterized by an insatiable hunger or hyperphagia and a constant need for food, leading to obesity. However, intranasal Carbetocin did not demonstrate a statistically significant improvement over placebo to week 12 on the Hyperphagia Questionnaire for Clinical Trials, the company said.The firm noted that the safety and tolerability of intranasal Carbetocin were consistent with those observed in previous clinical trials, with a low rate of adverse events.Shares of the company tumbled 11% in the pre-market session. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ACAD">ACAD stock</a> stayed within the ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘normal’ levels.Acadia’s Head of Research and Development, Elizabeth HZ Thompson, said that the company is “disappointed” by these findings. “We are committed to sharing a summary of the data in the future to ensure learning for the PWS community; however, given these results, we do not intend to investigate intranasal carbetocin any further,” Thompson added.CEO Catherine Owen Adams highlighted that the firm’s approved products are projected to generate over $1 billion in net sales in 2025 despite the disappointment with the trial. The company’s drugs for the treatment of Rett syndrome and for treating hallucinations and delusions associated with Parkinson’s disease psychosis are approved by the U.S. Food and Drug Administration.“Looking ahead, we anticipate seven Phase 2 or 3 study starts through 2026 and four data readouts by the end of 2027,” the CEO added.ACAD stock is up 29% this year and approximately 49% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-is-mp-materials-stock-rising-today/chD1R9FR330">Why Is MP Materials Stock Rising Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, an Acadia Pharmaceuticals company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Acadia Pharmaceuticals’ Investigational Drug For Rare Genetic Disorder Fails In Late-Stage Study 

The company noted that the safety and tolerability of intranasal Carbetocin were consistent with those observed in previous clinical trials.

Moderna (MRNA) said on Tuesday that its 2025-2026 formula of mNEXSPIKE demonstrated a strong immune response in recipients in a study.The updated formulation targets the LP.8.1 variant of the COVID-19-causing virus. Data from an ongoing phase 4, post-marketing study showed that the updated formula of mNEXSPIKE, on average, demonstrated a greater than 16-fold increase in neutralizing antibodies against the LP.8.1 variant, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://feeds.issuerdirect.com/news-release.html?newsid=6125971827149873&amp;symbol=MRNA">said</a>.A robust immune response was identified in individuals aged 12 to 64 years with at least one underlying condition that puts them at high risk for severe outcomes from an infection, as well as in all adults aged 65 years and older, the company added. The trial was evaluating the safety, tolerability, and immunogenicity of the new formula of mNEXSPIKE.<a href="https://stocktwits.com/symbol/MRNA">MRNA shares</a> rose over 1% in the pre-market session at the time of writing. On Stocktwits, retail sentiment around MRNA stayed within ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘normal’ levels.Moderna stated that the safety profile of the vaccine in the study was consistent with that observed in previous studies. mNEXSPIKE received the approval of the U.S. Food and Drug Administration in late May.Earlier this month, the company also announced that the 2025-2026 formula of its other COVID-19 vaccine, Spikevax, showed, on average, a greater than 8-fold increase in neutralizing antibodies against the LP.8.1 variant in individuals participating in a Phase 4 study.Spikevax is approved by the FDA for individuals six months through 64 years of age with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19, and all adults 65 years of age and older. mNEXSPIKE is only approved for individuals who are at least 12 years of age.MRNA stock is down 36% this year and approximately 59% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tesla-stock-rises-pre-market-after-ubs-raises-q3-delivery-estimate-mizuho-hikes-price-target/chDhMRBR35d">Tesla Stock Rises Pre-Market After UBS Raises Q3 Delivery Estimate, Mizuho Hikes Price Target</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, Moderna’s logo is displayed on a smartphone with an economic stock exchange index graph in the background. (Photo Illustration by Budrul Chukrut/SOPA Images/LightRocket via Getty Images)

Moderna Says Updated mNEXSPIKE Covid Shot Demonstrated Robust Immune Response In Study 

The trial was evaluating the safety, tolerability, and immunogenicity of the new formula of mNEXSPIKE.

AOR
iShares Core Growth Allocation ETF

Feed

News

Sentiment

Fundamentals

Info

Latest AOR News

AORiShares Core Growth Allocation ETF